Skip to website navigation Skip to article navigation Skip to content

A page refresh occures when a subject is selected.

Skip article navigation.

Disease areas and solutions



One condition which disproportionally affects women is osteoporosis, characterized by low bone mass and deterioration of bone micro-architecture. This makes the bones weak and fragile and increases the risk of fractures. UCB is committed to delivering solutions that can improve the lives of patients living with this condition. By investing in treatment and therapies, as well as in bone research, innovation, post-fracture care and education, we can collectively deliver solutions that make a positive impact on patients’ lives.

In 2020, UCB conducted a survey of almost 1 000 women [1] aged 60+ to better understand their experiences with osteoporosis – and the results suggested that many (65 percent) feel that the condition is neglected. 85 percent of the survey’s respondents also agreed that healthcare authorities should do more to prioritize osteoporosis, with many speculating that the condition would be more of a priority if it affected younger people as well.

These findings also echoed concerns raised by healthcare professionals: another UCB survey [2]  of bone specialists published, also conducted in 2020, found that 66 percent see osteoporosis as a neglected condition, with only 10 percent of specialists believing that osteoporosis and fragility fractures are currently given a high enough priority by their local health authority.

Evenity® [3] (romosozumab), a bone forming monoclonal antibody for the treatment of osteoporosis had its first European launch in March 2020. Evenity® is co-developed and co-commercialized by UCB and Amgen.

  • 1
  • 2
  • 3 Approved in the E.U., Israel, Hong Kong, Macau and Switzerland for treatment of severe osteoporosis in postmenopausal women at high risk of fracture. Approved in U.S., Canada, Taiwan, UAE, Thailand, Qatar and Brazil for the treatment of osteoporosis in postmenopausal women at high risk for fracture. Approved in Japan and South Korea for the treatment of osteoporosis for women and men at high risk for fracture. Approved in Australia for the treatment of osteoporosis in postmenopausal women at high risk of fracture and as a treatment to increase bone mass in men with osteoporosis at high risk of fracture.